Home > Boards > US Listed > Biotechs > MERSANA THERAPEUTICS, INC. (MRSN)

Potential competitor MEDI4276 flames out...

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jaybe Member Profile
 
Followed By 5
Posts 285
Boards Moderated 0
Alias Born 05/29/11
160x600 placeholder
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/16/2021 6:02:00 AM
Is Mersana Stock a Buy Right Now? This Is What You Need to Know TipRanks - 9/13/2021 4:20:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2021 7:51:32 AM
Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 9/7/2021 8:00:00 AM
Mersana Therapeutics to Provide Update on the Progress of its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I Study GlobeNewswire Inc. - 9/1/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/24/2021 4:31:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/18/2021 4:32:54 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/18/2021 4:31:25 PM
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 8/18/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/16/2021 8:17:02 AM
Mersana Therapeutics Announces Appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer GlobeNewswire Inc. - 8/16/2021 8:00:00 AM
Mersana Therapeutics EPS misses by $0.09 Seeking Alpha - 8/6/2021 6:04:38 AM
Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 8/6/2021 6:00:00 AM
Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/4/2021 8:00:00 AM
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates GlobeNewswire Inc. - 7/30/2021 8:00:00 AM
Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer GlobeNewswire Inc. - 7/28/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:32:28 PM
The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’ TipRanks - 6/29/2021 11:13:37 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2021 4:31:46 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2021 6:31:32 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:36:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:04:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:04:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:03:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:02:44 PM
jaybe   Thursday, 03/08/18 10:29:38 PM
Re: None
Post # of 42 
Potential competitor MEDI4276 flames out...

The wait is over for long overdue clinical data on AZD's "next-gen" Her-2 ADC MEDI4276. Published Phase 1 results this week at TAT demonstrated an ORR of 5% with DLTs and MTD at higher doses. This result most likely signals the end for this candidate as competitors such as DS-8201 already show ORR's over 50% in a similar population (3L), with 31% ORR for Her2-low.

XMT-1522 will need to clear 50% Her2+ and 30% Her2-low hurdles, with differentiating benefits, to be competitive. In the near term only DS-8201, SYD985, and PF-06804103 are "best-in-class" ADC competitors to keep an eye on.

https://academic.oup.com/annonc/article/29/suppl_3/mdy048.005/4917517?searchresult=1


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences